Document Detail


Phenotypic predictors of response to simvastatin therapy among African-Americans and Caucasians: the Cholesterol and Pharmacogenetics (CAP) Study.
MedLine Citation:
PMID:  16516587     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Although statins are effective lipid-lowering agents, the phenotypic and demographic predictors of such lowering have been less well examined. We enrolled 944 African-American and white men and women who completed an open-label, 6-week pharmacogenetics trial of 40 mg of simvastatin. The phenotypic and demographic variables were examined as predictors of the change in lipids and lipoproteins using linear regression analysis. On average, treatment with simvastatin lowered low-density lipoprotein (LDL) cholesterol by 54 mg/dl and increased high-density lipoprotein (HDL) cholesterol by 2 mg/dl. Compared with African-Americans, whites had a 3-mg/dl greater LDL reduction and a 1-mg/dl higher HDL elevation, independent of other variables, including baseline lipoprotein levels (p <0.01). Multivariate analyses revealed moderate subgroup differences, with older participants having a larger decrease in LDL cholesterol and apolipoprotein B levels compared with younger participants (p <0.001), women having larger increases in HDL than men (p <0.01), nonsmokers having larger decreases in LDL and triglyceride levels compared with smokers (p <0.05), those with hypertension having smaller decreases in apolipoprotein B than those without hypertension (p <0.05), and those with a larger waist circumference having a diminished lowering of triglycerides in response to treatment with simvastatin (p <0.01). In conclusion, treatment with simvastatin produced favorable lipid and lipoprotein changes among all participants. The magnitude of the lipid and lipoprotein responses, however, differed among participants according to a number of phenotypic and demographic characteristics.
Authors:
Joel A Simon; Feng Lin; Stephen B Hulley; Patricia J Blanche; David Waters; Stephen Shiboski; Jerome I Rotter; Deborah A Nickerson; Huiying Yang; Mohammed Saad; Ronald M Krauss
Related Documents :
19149567 - Emerging strategies and agents to lower cardiovascular risk by increasing high density ...
8020077 - Plasma lipids and lipoprotein-cholesterol distribution in nephrotic syndrome patients d...
9626027 - Remnant-like particle cholesterol levels in patients with dysbetalipoproteinemia or cor...
19013187 - Impact of progressive resistance training on lipids and lipoproteins in adults: a meta-...
12523567 - A complex, cross-taxon, chemical releaser of antipredator behavior in amphibians.
18258237 - Prediction of cardio- and cerebro-vascular events in patients with subclinical carotid ...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2006-01-27
Journal Detail:
Title:  The American journal of cardiology     Volume:  97     ISSN:  0002-9149     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  2006 Mar 
Date Detail:
Created Date:  2006-03-06     Completed Date:  2006-04-14     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  843-50     Citation Subset:  AIM; IM    
Affiliation:
General Internal Medicine Section, Medical Service, Veterans Affairs Medical Center, San Francisco, California, USA. jasimon@itsa.ucsf.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
African Americans*
Age Factors
Anticholesteremic Agents / administration & dosage,  pharmacology,  therapeutic use*
Apolipoprotein A-I / blood,  drug effects
Apolipoproteins B / blood,  drug effects
Cholesterol, HDL / blood,  drug effects
Cholesterol, LDL / blood,  drug effects
Demography
European Continental Ancestry Group*
Female
Humans
Hypercholesterolemia / drug therapy*,  ethnology,  genetics
Hypertension / complications
Male
Middle Aged
Peptide Fragments / blood,  drug effects
Phenotype
Sex Factors
Simvastatin / administration & dosage,  pharmacology,  therapeutic use*
Smoking / blood
Treatment Outcome
Triglycerides / blood
Grant Support
ID/Acronym/Agency:
U01-HL69757/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Anticholesteremic Agents; 0/Apolipoprotein A-I; 0/Apolipoproteins B; 0/Cholesterol, HDL; 0/Cholesterol, LDL; 0/Peptide Fragments; 0/Triglycerides; 0/apolipoprotein B (3304-3317); 79902-63-9/Simvastatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Impact of dysglycemia, body mass index, and waist-to-hip ratio on the prevalence of systemic hyperte...
Next Document:  Potential impact on cardiovascular public health of over-the-counter statin availability.